Injectable versions of some widely used cancer drugs may be excluded from the new Medicare price negotiations until the 2030s, Reuters reported July 28.
Read the full post on Becker's Hospital Review - Healthcare News
Some injectable drugs to sidestep Medicare negotiations until 2030s
